4 recruiting, 4 terminated, 1 completed. 4 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Tumor Treating Fields Therapy: new trials by email Literature Review of Tumor Treating Fields Therapy trials Research Report on Tumor Treating Fields Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial Radiation Therapy, Radiosurgery, Stereotactic Biopsy - Malignant Glioma | Phase 1 | Recruiting | Mayo Clinic | 28 | 2023-05-23 | 2026-09-30 |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 1 | Terminated | Emory University | 1 | 2022-10-13 | 2026-04-23 |
| Tumor Treating Fields for the Treatment of Brainstem Gliomas Optune device - Glioma | Not applicable | Recruiting | Emory University | 10 | 2022-05-11 | 2026-10-19 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer Questionnaire Administration, Tumor Treating Fields Therapy - Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2019-06-11 | 2023-10-30 |
| Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma Temozolomide, Radiation Therapy, NovoTTF-200A Device - Glioblastoma | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 30 | 2018-05-04 | 2025-05-15 |
| Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Bevacizumab, TTFields Therapy - Glioblastoma, Glioma | Phase 2 | Terminated | RTOG Foundation, Inc. | 3 | 2017-05-09 | 2021-06-02 |
Glioma (3) · Glioblastoma (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gliosarcoma (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Uveal Melanoma (1)
Emory University (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (1) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · RTOG Foundation, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (9) · Canada (1)
Apostolia M Tsimberidou (1) · Daniel M. Trifiletti, MD (1) · Jim Zhong, MD (1) · Manmeet Ahluwalia, MD, FACP (1) · Mohammad K Khan, MD, PhD (1) · Nina N Sanford (1) · Siqing Fu (1) · Timur Mitin, MD (1) · Wenyin Shi, MD (1)
PMID 32206976, PMID 35574391, PMID 36355259
P30CA138292 (2), P30CA016672 (1), U10CA180868 (1)